Researchers at Imperial College London and Apollo Therapeutics are developing a potential treatment for pulmonary arterial hypertension, David Silverman, Imperial College New, May 5, 2025

Imperial College London is working with Apollo Therapeutics to develop a prospective monoclonal antibody treatment for pulmonary arterial hypertension (PAH). The potential treatment is based on a protein that was identified in original research by the university, and is currently undergoing a proof of concept trial at Hammersmith Hospital, part of Imperial College Healthcare NHS Trust. To be followed!

Read more at this link on Imperial College News

TRANSLATE »
Scroll to Top